I-Mab Advances Antibody Uliledlimab in US, China

 I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics, today announced multiple clinical advancements for its proprietary and highly differentiated CD73 antibody, uliledlimab (also known as TJD5, or TJ004309) in advanced solid tumors. The Company plans to present detailed clinical results at select scientific conferences this year.

https://www.biospace.com/article/releases/i-mab-announces-multiple-clinical-advancements-of-its-differentiated-cd73-antibody-uliledlimab-in-china-and-the-u-s-/